FI111250B - Menetelmä terapeuttisesti käyttökelpoisen N-metyyli-3-fenyyli-3-(2-metyylitiofenoksi)propyyliamiinin valmistamiseksi - Google Patents

Menetelmä terapeuttisesti käyttökelpoisen N-metyyli-3-fenyyli-3-(2-metyylitiofenoksi)propyyliamiinin valmistamiseksi Download PDF

Info

Publication number
FI111250B
FI111250B FI924305A FI924305A FI111250B FI 111250 B FI111250 B FI 111250B FI 924305 A FI924305 A FI 924305A FI 924305 A FI924305 A FI 924305A FI 111250 B FI111250 B FI 111250B
Authority
FI
Finland
Prior art keywords
phenyl
compound
methylthiophenoxy
formula
methyl
Prior art date
Application number
FI924305A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI924305A0 (fi
FI924305L (fi
Inventor
David Taiwai Wong
David Wayne Robertson
Donald Richard Gehlert
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of FI924305A0 publication Critical patent/FI924305A0/fi
Publication of FI924305L publication Critical patent/FI924305L/fi
Application granted granted Critical
Publication of FI111250B publication Critical patent/FI111250B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/48—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/29—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C323/18—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/20—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
FI924305A 1991-09-27 1992-09-25 Menetelmä terapeuttisesti käyttökelpoisen N-metyyli-3-fenyyli-3-(2-metyylitiofenoksi)propyyliamiinin valmistamiseksi FI111250B (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/766,993 US5281624A (en) 1991-09-27 1991-09-27 N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof
US76699391 1991-09-27

Publications (3)

Publication Number Publication Date
FI924305A0 FI924305A0 (fi) 1992-09-25
FI924305L FI924305L (fi) 1993-03-28
FI111250B true FI111250B (fi) 2003-06-30

Family

ID=25078150

Family Applications (1)

Application Number Title Priority Date Filing Date
FI924305A FI111250B (fi) 1991-09-27 1992-09-25 Menetelmä terapeuttisesti käyttökelpoisen N-metyyli-3-fenyyli-3-(2-metyylitiofenoksi)propyyliamiinin valmistamiseksi

Country Status (23)

Country Link
US (1) US5281624A (enExample)
EP (1) EP0534756A3 (enExample)
JP (2) JPH05238996A (enExample)
KR (1) KR100221180B1 (enExample)
CN (1) CN1033580C (enExample)
AT (1) ATE124934T1 (enExample)
AU (1) AU655075B2 (enExample)
BR (2) BR9203743A (enExample)
CA (2) CA2079161C (enExample)
CZ (1) CZ281817B6 (enExample)
DE (1) DE69203424T2 (enExample)
FI (1) FI111250B (enExample)
HU (1) HU215519B (enExample)
IL (1) IL103277A (enExample)
MX (1) MX9205433A (enExample)
MY (1) MY108304A (enExample)
NO (1) NO178109C (enExample)
NZ (1) NZ244460A (enExample)
RU (1) RU2057120C1 (enExample)
SK (1) SK290892A3 (enExample)
TW (1) TW249225B (enExample)
YU (1) YU87192A (enExample)
ZA (1) ZA927240B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6017965A (en) * 1993-02-08 2000-01-25 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
US6071970A (en) * 1993-02-08 2000-06-06 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
US7087765B2 (en) * 1995-06-07 2006-08-08 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
TW344661B (en) * 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
IL122984A0 (en) * 1995-07-24 1998-08-16 Lilly Co Eli Treatment of attention-deficit/ hyperactivity disorder
EP0927034A1 (en) * 1996-09-19 1999-07-07 American Home Products Corporation Method of treating urinary incontinence
EA200001049A1 (ru) * 1998-04-09 2001-04-23 Фармация Энд Апджон Компани Новые способы лечения нервных расстройств
US6586427B2 (en) 1998-04-09 2003-07-01 Pharmacia & Upjohn Company Treatments for nervous disorders
US6342533B1 (en) 1998-12-01 2002-01-29 Sepracor, Inc. Derivatives of (−)-venlafaxine and methods of preparing and using the same
CA2368083A1 (en) 1999-04-06 2000-10-12 Sepracor Inc. Derivatives of venlafaxine and methods of preparing and using the same
JP3893878B2 (ja) * 1999-05-24 2007-03-14 三菱ウェルファーマ株式会社 フェノキシプロピルアミン化合物
ATE305788T1 (de) * 1999-07-01 2005-10-15 Pharmacia & Upjohn Co Llc (s,s)-reboxetin zur behandlung von inkontinenz
US20040034106A1 (en) * 2001-11-06 2004-02-19 Read Holly Ann Treatment of anxiety disorders
US20050014843A1 (en) * 2001-11-30 2005-01-20 Allen Albert John Use of norepinephrine reuptake inhibitors for the treatment of tic disorders
JP2005517647A (ja) * 2001-12-11 2005-06-16 イーライ・リリー・アンド・カンパニー ノルエピネフリン再取り込み阻害物質の認知不全処置への使用
CA2519379A1 (en) * 2003-04-04 2004-10-21 Dynogen Pharmaceuticals, Inc. Method of treating lower urinary tract disorders
WO2005020976A2 (en) * 2003-08-27 2005-03-10 Eli Lilly And Company Treatment of pervasive developmental disorders with norepinephrine reuptake inhibitors
KR20060121178A (ko) * 2003-12-12 2006-11-28 일라이 릴리 앤드 캄파니 일과성 전신 열감, 충동 조절 장애 및 일반적인 의학상태로 인한 인격 변화 치료용 선택적 노르에피네프린재흡수 억제제
ITMI20061987A1 (it) * 2006-10-16 2008-04-17 Archimica Srl Processo per la sintesi di arilossipropilammine ed eteroarilossipropilammine.
EP3697754A1 (en) * 2017-10-16 2020-08-26 Esteve Pharmaceuticals, S.A. Propanamine derivatives for treating pain and pain related conditions
CN113121394B (zh) * 2019-12-30 2022-11-08 中国药科大学 一种苯氧乙酸类衍生物的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4626549A (en) * 1974-01-10 1986-12-02 Eli Lilly And Company Treatment of obesity with aryloxyphenylpropylamines
US4018895A (en) * 1974-01-10 1977-04-19 Eli Lilly And Company Aryloxyphenylpropylamines in treating depression
US4584404A (en) * 1974-01-10 1986-04-22 Eli Lilly And Company Substituted phenoxyphenylproply dimethylamines
US4194009A (en) * 1974-01-10 1980-03-18 Eli Lilly And Company Aryloxyphenylpropylamines for obtaining a psychotropic effect
US4313896A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Aryloxyphenylpropylamines
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
CA1337128C (en) * 1988-04-08 1995-09-26 David Wayne Robertson Propanamine derivatives

Also Published As

Publication number Publication date
FI924305A0 (fi) 1992-09-25
EP0534756A3 (en) 1993-06-16
BR9203743A (pt) 1993-04-20
ATE124934T1 (de) 1995-07-15
DE69203424D1 (de) 1995-08-17
NO923710L (no) 1993-03-29
AU655075B2 (en) 1994-12-01
JP3256291B2 (ja) 2002-02-12
IL103277A0 (en) 1993-02-21
US5281624A (en) 1994-01-25
MY108304A (en) 1996-09-30
CN1033580C (zh) 1996-12-18
SK280480B6 (sk) 2000-02-14
CA2079162A1 (en) 1993-03-28
JPH05238996A (ja) 1993-09-17
DE69203424T2 (de) 1996-01-11
SK290892A3 (en) 2000-02-14
NO923710D0 (no) 1992-09-24
CZ281817B6 (cs) 1997-02-12
HUT65375A (en) 1994-05-02
FI924305L (fi) 1993-03-28
CZ290892A3 (en) 1993-04-14
NO178109C (no) 1996-01-24
KR100221180B1 (ko) 1999-09-15
IL103277A (en) 1997-11-20
KR930005972A (ko) 1993-04-20
EP0534756A2 (en) 1993-03-31
HU9203051D0 (en) 1992-12-28
TW249225B (enExample) 1995-06-11
CA2079161A1 (en) 1993-03-28
RU2057120C1 (ru) 1996-03-27
AU2537092A (en) 1993-04-01
NZ244460A (en) 1994-10-26
CA2079161C (en) 2004-02-17
ZA927240B (en) 1994-03-22
YU87192A (sh) 1995-10-24
CN1071416A (zh) 1993-04-28
HU215519B (hu) 1999-01-28
MX9205433A (es) 1993-03-01
BR1100384A (pt) 1999-08-31
JPH05201961A (ja) 1993-08-10
NO178109B (no) 1995-10-16

Similar Documents

Publication Publication Date Title
US5281624A (en) N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof
FI77018B (fi) Analogifoerfarande foer framstaellning av antidepressivt aktiv (-)-enantiomer av n-metyl-n-/3-(2-metylfenoxi) -3-fenylpropyl/amin och dess farmaceutiskt godtagbara salt.
US4626549A (en) Treatment of obesity with aryloxyphenylpropylamines
EP0405834A2 (en) Tetrazole excitatory amino acid receptor antagonists
JPH07149644A (ja) 血管形成および血管形成性疾患を抑制する方法
DE68917357T2 (de) Derivate der Coffeinsäure und pharmazeutische Zusammensetzungen, die sie enthalten.
RU2001911C1 (ru) Способ получени замещенных 1,2,3,4-тетрагидронафталинов или их фармацевтически приемлемых аддитивных солей кислоты
NZ211146A (en) 2,5-diaryl-tetrahydrothiophene derivatives and pharmaceutical compositions
DE69600709T2 (de) Verbindungen mit N-Acyliertem Piperidin in der Seitenkette und Zusammensetzungen
JP2000034230A (ja) 含硫黄抗真菌剤
EP0537915B1 (en) N-alkyl-3-phenyl-3-(2-alkylthiophenoxy)propylamines as norepinephrine inhibitors
US5804589A (en) Use of N-cyclohexyl benzamides for treating bowel disorders
DE3879402T2 (de) Selektive sertonin-aufnahme-inhibitoren.
EP0591581B1 (en) N-Alkyl-3-phenyl-3-(2-alkylthiophenoxy)propylamines
JP2005538951A (ja) ケイ皮酸二量体、その製造方法及び退行性脳疾患治療のためのその用途
EP0034521B1 (fr) Médicament analgésique contenant de la 1-(3'benzofuryl)-4-benzylpipérazine et son procédé de préparation
JP3857428B2 (ja) 抗真菌剤
US20040266785A1 (en) KMST isoeugenol derivatives and pharmaceutical activity
CH633774A5 (en) Phloroglucinol derivatives, their process and their application in therapeutics
AT337161B (de) Verfahren zur herstellung von neuen 3-phenoxy-3-phenylpropylaminen und deren saureadditionssalzen
US20040266786A1 (en) Compound eugenosedin-a and antidepressants protect against lipopolysaccharide-induced shock
HK1008525A1 (en) Indole derivative as 5-ht1a antagonist and as inhibitors of serotonine reuptake
HK1008525B (en) Indole derivative as 5-ht1a antagonist and as inhibitors of serotonine reuptake